2026-04-29T12:24:10Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/142922024-09-27T21:43:50Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Ruiz García, Yara author Sohn, Woo-Yun author Seib, Kate L author Taha, Muhamed-Kheir author Vazquez-Moreno, Julio Alberto author Silva de Lemos, Ana Paula author Vadivelu, Kumaran author Pizza, Mariagrazia author Rappuoli, Rino author Bekkat-Berkani, Rafik author 2021-10-29 Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80-90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B meningococcal and gonococcal strains. This comprehensive review summarizes scientific evidence on the genotypic and phenotypic similarities between vaccine antigens and their homologs expressed by non-B meningococcal and gonococcal strains. It also includes immune responses of 4CMenB-vaccinated individuals and effectiveness and impact of 4CMenB against these strains. Varying degrees of strain coverage were estimated depending on the non-B meningococcal serogroup and antigenic repertoire. 4CMenB elicits immune responses against non-B meningococcal serogroups and N. gonorrhoeae. Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization. In conclusion, functional antibody activity and real-world evidence indicate that 4CMenB has the potential to provide some protection beyond MenB disease. NPJ Vaccines 2021 Oct 29;6(1):130. 10.1038/s41541-021-00388-3 2059-0105 NPJ Vaccines 34716336 http://hdl.handle.net/20.500.12105/14292 Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect